Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Janux Therapeutics, Inc. (JANX)
A forensic read on Janux Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Grey Zone
Financial health
16.6
Distress distance
Clean
Earnings quality
3
Forensic signals
-9.7
P / E (ttm)
-11.9%
ROE
$1.0B
Market cap
0.00%
Dividend yield
-5.6%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Janux Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 16.6, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+41.7%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +41.7% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. This is the third straight fiscal year of building accruals — a multi-year streak is a materially stronger tell than a single year's move. The cash-flow cross-check is more mixed: reported earnings ran in line with operating cash by 4% of net operating assets, diverging from the balance-sheet accrual read.
+14.3%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +49% over the last 3 years to FY2025 (+14.3%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~14.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~33%.
402% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 402% of revenue in FY2025 — about $0.65 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 14.5% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.
Key fundamentals
Latest Revenue$10.0M
Revenue Growth YoY-5.6%
Revenue CAGR (3yr)+5.1%
Net Margin-1136.2%
Free Cash Flow-$83.3M
Return on Equity-11.9%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Janux Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?